Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.
https://www.pharmalive.com/wp-content/uploads/2022/12/neuropathicpain.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-12-22 09:07:452022-12-22 09:07:45Lexicon's AAK1 inhibitor disappoints in Phase II postherpetic neuralgia study
